Loading the company…
Loading the company…
In the last ten years FDA made 3 decisions for Next Science (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2021 (2). The latest was on 2021-09-23.
| Family | Decisions on record |
|---|---|
| Skin substitutes & wound grafts | 4 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2021-09-23 | 510(k) | K203446 | TorrentX Wound Wash |
| 2021-04-23 | 510(k) | K203835 | MIS Solution |
| 2017-03-06 | 510(k) | K163188 | Next Science Wound Gel (Rx) |
| 2015-12-17 | 510(k) | K150792 | Next Science Wound Gel |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Next Science.
In 2025, Next Science reported engagement with 415 surgeons and other clinicians in the states MedaRep covers, worth $524K in consulting, speaking, meals and travel for its device products, the most in Texas ($164K to 57). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Texas ($164K, 57 engaged), Georgia ($121K, 9 engaged), New Jersey ($112K, 24 engaged), Illinois ($97K, 38 engaged), New York ($6,286, 46 engaged).